Table A3.
Resistance rates of sequence type 131 and non-sequence type 131 isolates in the 102 patients with liver cirrhosis and bacteremia caused by ESBLEC and NESBLEC.
| ESBLEC | NESBLEC | |||||
|---|---|---|---|---|---|---|
| Antimicrobials | ST 131 a (n = 18) |
Non-ST 131 a (n = 33) |
p Value | ST 131 a (n = 0) |
Non-ST 131 b (n = 51) |
p Value |
| Amikacin | 1 | 11 | 0.04 | NA | 0 | NA |
| Gentamicin | 9 | 26 | 0.03 | NA | 8 | NA |
| Ciprofloxacin | 17 | 25 | 0.09 | NA | 10 | NA |
| Imipenem | 0 | 0 | 1.0 | NA | 0 | NA |
| Ampicillin–sulbactam | 16 | 30 | 0.8 | NA | 26 | NA |
| Cefoxitin | 6 | 21 | 0.04 | NA | 10 | NA |
| TMP–SMZ b | 8 | 25 | 0.03 | NA | 23 | NA |
| Tigecycline | 0 | 1 | 1.0 | NA | 0 | NA |
| Minocycline | 0 | 15 | <0.001 | NA | 21 | NA |
| Ciprofloxacin and TMP–SMZ b | 7 | 19 | 0.2 | NA | 6 | NA |
| Ciprofloxacin and gentamicin | 8 | 21 | 0.2 | NA | 4 | NA |
| TMP–SMZ b and gentamicin | 2 | 21 | <0.001 | NA | 5 | NA |
a ST131: sequence type 131. b TMP–SMZ: trimethoprim–sulfamethoxazole.